BridgeMD
GliflOzin in eLderly Diabetic patiENts: A praGmatic intraclass Evaluation trial
EU CTIS ID: 2024-518915-20-00
What this study is testing
The primary objective is to compare the proportion of patients treated with each SGLT2i drug, who achieve the individualized HbA1c target without level-3 hypoglycaemia at the end of the study at 24 months0
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Type 2 diabetes
- Age >=70 years
- Men or women
- Established cardiovascular disease (symptomatic or asymptomatic) or eGFR <90 ml / min / 1.73 m2 but above the threshold for starting therapy with all SGLTe inhibitors
- HbA1c higher than the individualized target value
- Clinical indication when starting a therapy with SGLT2i
You likely can't join if
- Age> 90 years
- Estimated life expectancy <1 year
- Very high risk of urinary infections (more than 2 episodes in the last 6 months)
- Recent unintentional weight loss (> 5% in <6 months)
- Participation in another interventional drug trial
- Inability to give written informed consent
See the full eligibility criteria
- Type 2 diabetes
- Age >=70 years
- Men or women
- Established cardiovascular disease (symptomatic or asymptomatic) or eGFR <90 ml / min / 1.73 m2 but above the threshold for starting therapy with all SGLTe inhibitors
- HbA1c higher than the individualized target value
- Clinical indication when starting a therapy with SGLT2i
- Ability to give written informed consent.
- Age> 90 years
- Estimated life expectancy <1 year
- Very high risk of urinary infections (more than 2 episodes in the last 6 months)
- Recent unintentional weight loss (> 5% in <6 months)
- Participation in another interventional drug trial
- Inability to give written informed consent
- Intolerance to lactose and any other contraindication to the study drugs
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.